Vinyas Innovativ Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 Aug 2026 | Industrial Manufacturing | Market Cap: ₹2.0K Cr
Vinyas expects a 25% year-on-year revenue growth for FY ’26. - Current order inflow is expected to be at similar levels as FY ’25, around Rs. Vinyas Innovative Technologies anticipates 25% year-on-year revenue growth for FY '26.
From Vinyas Innovativ's Q4 FY25 earnings-call transcript · updated 26 Aug 2026.
Price
₹1,657
Market Cap
₹2.0K Cr
P/E Ratio
65.7
How does Vinyas Innovativ rank in Industrial Manufacturing?
Compare Vinyas Innovativ against every Industrial Manufacturing company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
- →Vinyas expects a 25% year-on-year revenue growth for FY ’26.
- →Current order inflow is expected to be at similar levels as FY ’25, around Rs. 600 to 750 crores.
- →The confirmed order book is anticipated to grow from Rs. 1,018 crores to about Rs. 1,500 to 1,600 crores by the end of FY ’26.
- →Full optimal utilization of current capacity is expected by FY ’27.
- →Current capacity can support Rs. 1,200 to 1,400 crores in revenue without incremental investment.
- →The company targets Rs. 1,000+ crore revenue by FY ’27 but is cautious in committing exact figures.
- →There is a 25%-30% year-on-year growth projected over the next few years.
- →Order execution timelines span 12 to 18 months primarily.
- →Expansion into new segments like commercial aerospace and medical devices aims to support growth.
📈 Profitability & Margins
- →Vinyas Innovative Technologies anticipates 25% year-on-year revenue growth for FY '26.
- →EBITDA margin is expected to remain stable between 9% to 11% over the next 2-3 years.
- →Net profit growth of 27% was achieved in FY '25, indicating strong profitability momentum.
- →EPS for FY '25 was 15.43, with a second half EPS of 9.86, reflecting improved performance.
- →The margin profile is expected to stay consistent for the next two to three years with operational efficiencies.
- →Potential margin improvement is limited in the near term; any increases would take more time.
- →The company plans to leverage growth from defense and aerospace sectors and the medical device segment.
- →Working capital and capacity expansions are in line to support growing order books without significant margin dilution.
🏗️ Capital Expenditure Plans
- →Incremental CAPEX mainly involves adding more SMT lines, with a rule of thumb of Rs. 600 crores revenue per SMT line on defense and aerospace side.
- →Recent expansion involved Rs. 30 crores CAPEX to add a second SMT line; similar level expected for each new line.
- →Yearly CAPEX of Rs. 2-3 crores planned for other critical equipment to support programs.
- →Current capacity expansion can support Rs. 1,200 to Rs. 1,400 crores revenue without major additional CAPEX.
- →Working capital is sufficient for this and next financial year; additional funding to be explored afterward as needed.
- →No major backward integration CAPEX currently planned, as electronic components are low volume and predominantly imported.
- →Future investments also include equipment upgrades for quality and process improvements as programs mature.
💰 Fundraising & Capital Structure
- →No explicit mention of any new fundraising through debt or equity in the call transcript.
- →Current debt-to-equity ratio stands healthy at 0.7x.
- →Company has sufficient unutilized non-fund based bank limits for working capital and operational readiness.
- →Incremental CAPEX plans primarily focus on adding SMT lines (~Rs. 30 crore per line) and small critical equipment (~Rs. 2-3 crore yearly).
- →Working capital is currently sufficient to support growth for this and next financial year, with advances from customers helping the requirement.
- →Any major future financing needs will be assessed and communicated later as per evolving business needs.
📋 Order Book & Pipeline
- →Current order book stands at about Rs. 1,018 crores as of June 4, 2025.
- →Execution timeline for the order book is between 12 to 18 months.
- →Order inflow expected in FY '26 is between Rs. 600 to 750 crores, similar to FY '25 levels.
- →The confirmed order book is expected to grow to about Rs. 1,500 to 1,600 crores by the end of FY '26, reflecting 25% growth.
- →The order book composition is roughly 80% defense, 15-18% industrial, and the balance medical.
- →Approximately 80% of the order book pertains to Make in India programs, with most offset programs having largely completed.
- →Export orders make up about 22-23% of the current orders.
- →No substantial development has occurred this financial year on the build-to-spec side for medical devices.
Key Metrics
Frequently Asked Questions
What were Vinyas Innovativ Q4 FY25 results?
Vinyas expects a 25% year-on-year revenue growth for FY ’26. - Current order inflow is expected to be at similar levels as FY ’25, around Rs. Vinyas Innovative Technologies anticipates 25% year-on-year revenue growth for FY '26.
What is Vinyas Innovativ share price analysis?
Vinyas Innovativ currently shows a neutral. The stock trades at a P/E of 65.7 with a market cap of ₹2,028 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vinyas Innovativ planning capital expenditure?
Incremental CAPEX mainly involves adding more SMT lines, with a rule of thumb of Rs.
Keep Vinyas Innovativ on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.